Following FDA feedback, PTC Therapeutics withdrew its application for ataluren, intended for the treatment of nonsense mutation Duchenne muscular dystrophy.
SOUTH PLAINFIELD, N.J., Feb. 17, 2021 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 ...
WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results